Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Eastern District of Missouri on behalf of a class consisting of all persons or entities who purchased the securities of K-V Pharmaceutical Company (“K-V Pharmaceutical” or the “Company”) (NYSE:KV-A) (NYSE:KV-B), between February 14, 2011 and April 4, 2011, inclusive (the “Class Period”).

A copy of the Complaint is available from the court or from Glancy Binkow & Goldberg LLP. Please contact us by phone to discuss this action or to obtain a copy of the Complaint at 310-201-9150 or Toll Free at 888-773-9224, by email at shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

The Complaint charges K-V Pharmaceutical and certain of the Company’s executive officers with violations of federal securities laws. K-V Pharmaceutical is a specialty pharmaceutical company engaged in the acquisition, development, manufacture and marketing of branded and generic/non-branded prescription pharmaceutical products in the United States, primarily focusing on women’s healthcare. The Complaint alleges that during the Class Period defendants issued false and/or misleading statements concerning the Company’s business and financial prospects. Specifically, the Complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted K-V Pharmaceutical the exclusive distribution rights over “Makena,” a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing K-V Pharmaceutical’s competitors from distributing generic formulations of the drug. The Complaint further alleges that defendants failed to disclosed that the drug’s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups.

On March 17, 2011, U.S. Senators Amy Klobuchar and Sherrod Brown issued a press release regarding a letter they had sent to the Federal Trade Commission urging the agency to launch an investigation into potentially anti-competitive behavior related to the dramatic increased in Makena’s price. Following this news, K-V Pharmaceutical’s A-series stock dropped $1.14, from the previous day’s closing price of $9.64, to close at $8.50 per share on March 17, 2011.

On April 1, 2011, the Company announced a 55% reduction in Makena’s list price. Then, on April 4, 2011, Bloomberg published an article disclosing that even with the recently announced price reduction, prescribing physicians would not recommend Makena to their patients. Citing interviews with several physicians, Bloomberg reported that the hostility generated by Makena’s initial price had created a barrier to using K-V Pharmaceutical’s Makena as there was already a cheaper alternative available that the FDA stood behind.

Plaintiff seeks to recover damages on behalf of class members and is represented by Glancy Binkow & Goldberg LLP, a law firm with significant experience in prosecuting class actions, and substantial expertise in actions involving corporate fraud.

If you are a member of the class described above, you may move the Court, no later than 60 days from October 19, 2011, to serve as lead plaintiff; however, you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1801 Avenue of the Stars, Suite 311, Los Angeles, California 90067, by telephone at 310-201-9150 or Toll Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.